Omeros (NASDAQ:OMER) Earns Hold Rating from Needham & Company LLC

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reiterated by equities research analysts at Needham & Company LLC in a research note issued on Friday,Benzinga reports.

Several other brokerages have also issued reports on OMER. D. Boral Capital reiterated a “buy” rating and issued a $36.00 price target on shares of Omeros in a report on Tuesday, May 13th. StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Stock Performance

Shares of OMER opened at $3.21 on Friday. Omeros has a 52-week low of $2.97 and a 52-week high of $13.60. The business’s 50 day moving average price is $7.06 and its two-hundred day moving average price is $8.14. The firm has a market cap of $187.16 million, a PE ratio of -1.39 and a beta of 2.42.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Research analysts predict that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Truvestments Capital LLC lifted its holdings in shares of Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Omeros in the fourth quarter valued at approximately $46,000. Picton Mahoney Asset Management lifted its holdings in shares of Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 4,404 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Omeros by 14,486.3% in the first quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 7,388 shares in the last quarter. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.